RefleXion Medical Stock

www.reflexion.com/Healthcare / Medical DevicesFounded: 2009Funding to Date: $546.33MM

RefleXion develops a biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized.

Register To Buy and Sell Shares

For more details on financing and valuation for RefleXion Medical, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access RefleXion Medical’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like RefleXion Medical.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

RefleXion Medical investors also invested in these private companies

U.S. Department of Health and Human Services
Sofinnova Partners
Hillenbrand Capital Partners
KCK Group
Inspovation Ventures
Pimlico Pond Investments

Team

Management Team

Samuel Mazin Ph.D
Co-Founder & Chief Technology Officer
Todd Powell
President & Chief Executive Officer
Martyn Webster
Chief Financial Officer
Thorsten Melcher Ph.D
Chief Business Officer
Shervin Shirvani MD
Chief Medical Officer

Board Members

Antoine Papiernik
Sofinnova Partners
Nael Kassar
KCK Group

Frequently Asked Questions About RefleXion Medical’s Stock

plusminus
Can you buy RefleXion Medical’s stock?
RefleXion Medical is not publicly traded on NYSE or NASDAQ in the U.S. To buy RefleXion Medical’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell RefleXion Medical’s stock?
Yes, you can sell stock of a private company like RefleXion Medical. Forge can help you sell your RefleXion Medical stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is RefleXion Medical’s stock price?
RefleXion Medical is a privately held company and therefore does not have a public stock price. However, you may access RefleXion Medical’s private market stock price with Forge Data.
plusminus
What is RefleXion Medical’s stock ticker symbol?
RefleXion Medical does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

RefleXion Showcases Breakthrough SCINTIX Biology-Guided Radiotherapy and Highlights New Research at ASTRO 2023 Meeting
RefleXion® Medical, a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831). Researchers from multiple clinical programs will present new scientific evidence in 20 presentations, including two oral presentations, supporting the potential of SCINTIX therapy, which is delivered only through the X1 platform.
RefleXion acquires radiopharmaceutical rights from 3B Pharmaceuticals
RefleXion Medical has acquired the exclusive rights to develop and commercialize a specific molecule, RXM-4768, from 3B Pharmaceuticals. This molecule targets fibroblast activation proteins found in nearly all solid tumor types and could expand the patient population eligible for Scintix therapy. The deal includes upfront and annual license payments to 3B Pharmaceuticals, with additional payments upon certain milestones.
First cancer patient treated with RefleXion biology-guided radiotherapy
RefleXion Medical has announced the first patient has completed treatment using its Scintix biology-guided radiotherapy on its X1 machine. The treatment uses the individual biology of each tumor to determine the amount of radiation required, receiving FDA clearance in February of this year. The company expects to offer the treatment in specific cancer centers in California, Pennsylvania, and Texas soon, with New Jersey, Connecticut, and Oregon to follow by the end of 2023.
Updated on: Feb 29, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.